PTGS1 and colorectal cancer: Among the few selective COX-1 inhibitors investigated as potential analgesics and anti-platelet agents, mofezolac has been developed and marketed in Japan as a powerful pain killer [166], and its anticancer activity has been investigated almost exclusively in colorectal cancer experimental models.